Samotolisib

Samotolisib (LY3023414) is an orally bioavailable, ATP-competitive inhibitor targeting class I PI3K isoforms, DNA-PK, and mTOR. It has been investigated in preclinical and clinical studies for various solid tumors, including advanced breast and colon cancers, demonstrating research utility in both in vitro and in vivo models.

Product Specifications

CAS Number

1386874-06-1

Product Name Alternative

Autophagy, DNA-dependent protein kinase, DNAPK, DNA-PK, class I PI3K isoforms, Mammalian target of Rapamycin, GTPL 8918, GTPL8918, GTPL-8918, Inhibitor, inhibit, mTOR kinase, mTOR, LY 3023414, LY3023414, LY-3023414, PI3K, Phosphoinositide 3-kinase, Samotolisib

Field of Research

Cell Biology, Molecular Biology, Signal Transduction

Purity

98.41% (May vary between batches)

Solubility

H2O:< 1 mg/mL (insoluble or slightly soluble) ; Ethanol:57 mg/mL (140.23 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.92 mM) ; DMSO:50 mg/mL (123.01 mM)